XGN Stock Summary and Trading Ideas (Exagen | NASDAQ:XGN)

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Exagen trades on the NASDAQ stock market under the symbol XGN.

As of January 9, 2026, XGN stock price climbed to $6.34 with 428,629 million shares trading.

XGN has a beta of 1.17, meaning it tends to be more sensitive to market movements. XGN has a correlation of 0.06 to the broad based SPY ETF.

XGN has a market cap of $143.68 million. This is considered a Micro Cap stock.

Last quarter Exagen reported $17 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $244,000 and missed earnings estimates by -$.04.

In the last 3 years, XGN traded as high as $12.23 and as low as $1.30.

The top ETF exchange traded funds that XGN belongs to (by Net Assets): VTI, VXF, IWC, ROSC, DFAC.

XGN has outperformed the market in the last year with a price return of +92.7% while the SPY ETF gained +19.0%. However, in the short term, XGN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -42.8% vs +3.7% return in SPY. But in the last 2 weeks, XGN shares have fared better than the market returning +3.4% compared to SPY +0.5%.

XGN support price is $5.96 and resistance is $6.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XGN shares will trade within this expected range on the day.